Claims for Patent: 8,895,586

Summary for Patent: 8,895,586

Title:	Methods of treating emesis
Abstract:	Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the neurokinin (NK.sub.1) receptor. The compounds have the general formula (I): ##STR00001##
Inventor(s):	Fadini; Luca (Giubiasco, CH), Manini; Peter (Giubiasco, CH), Pietra; Claudio (Como, IT), Giuliano; Claudio (Como, IT), Lovati; Emanuela (Mendrisio, CH), Cannella; Roberta (Varese, IT), Venturini; Alessio (Varese, IT), Stella; Valentino J. (Lawrence, KS)
Assignee:
Application Number:	13/864,381
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,895,586
Patent Claims:	1. A method of treating emesis in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of the following compound: ##STR00036## or a pharmaceutically acceptable salt thereof. 2. The method of claim 1, wherein said emesis comprises chemotherapy-induced nausea and vomiting, radiotherapy-induced nausea and vomiting, or post-operative nausea and vomiting. 3. The method of claim 1, wherein said emesis is induced by moderately emetogenic chemotherapy. 4. The method of claim 1, wherein said emesis is induced by highly emetogenic chemotherapy. 5. The method of claim 1, wherein said emesis is acute and delayed emesis induced by moderately or highly emetogenic chemotherapy. 6. The method of claim 1, wherein said compound is administered via injection. 7. The method of claim 1, wherein said compound is administered at a dosage of from 10 to 200 mg. 8. The method of claim 1, further comprising administering palonosetron or a pharmaceutically acceptable salt thereof. 9. The method of claim 1, further comprising administering palonosetron or a pharmaceutically acceptable salt thereof and dexamethasone. 10. A method of treating emesis in a patient in need thereof, comprising administering to said patient via injection a therapeutically effective amount of the following compound: ##STR00037## or a pharmaceutically acceptable salt thereof. 11. The method of claim 10, wherein said emesis comprises chemotherapy-induced nausea and vomiting. 12. The method of claim 10, wherein said emesis is acute and delayed emesis induced by moderately or highly emetogenic chemotherapy. 13. The method of claim 10, wherein said compound is administered via injection at a dosage of from 10 to 200 mg. 14. A method of treating emesis in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of the following compound: ##STR00038## in combination with palonosetron or a pharmaceutically acceptable salt thereof and dexamethasone. 15. The method of claim 14, wherein said emesis comprises chemotherapy-induced nausea and vomiting. 16. The method of claim 14, wherein said compound is administered via injection. 17. The method of claim 14, wherein said compound is administered via injection at a dosage of from 10 to 200 mg. 18. A method of treating emesis in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of the following compound: ##STR00039## or a pharmaceutically acceptable salt thereof. 19. The method of claim 18, wherein said compound is administered via injection. 20. The method of claim 18, wherein said compound is administered at a dosage of from 10 to 200 mg. 21. The method of claim 18, further comprising administering palonosetron or a pharmaceutically acceptable salt thereof.